Sodium Ascorbate: Uses, Side Effects, Dosage - Drugvu

ℹ️ Compiled from public regulatory records · Last regulator revision: December 5, 2025🚩 Report this page

Sodium Ascorbate

Active ingredient

GB MHRA

Drug class: -
Availability: See label
Markets covered: 1
Products on record: 2

Overview

Sodium Ascorbate is an active pharmaceutical ingredient. The information below is compiled per regulator from the product labels on record, with direct links to the original documents.

Regulatory status by market

Market	Regulator	Products	Last revision
GB United Kingdom	MHRA	2	December 5, 2025

GBUnited Kingdom· MHRA

2 products

Uses

GBOfficial regulatory label· revised October 4, 2024[1]

Prevention and treatment of iron deficiency anaemia and for the simultaneous treatment of vitamin C deficiency.

How to take

Sources & citations

[1]MHRA (UK) · PL162500003 · revised October 4, 2024

Information on this page is compiled from public regulatory records. Drugvu is not affiliated with any regulator or pharmaceutical manufacturer. This is not medical advice. Always consult a qualified healthcare professional.

Side effects & warnings

GBOfficial regulatory label· Adverse reactions· revised October 4, 2024[1]

e. nausea, vomiting, abdominal pain or discomfort, blackening of stools, diarrhoea and/or constipation, but the incidence of side-effects is less owing to the prolonged release nature of the formulation. Isolated cases of allergic reaction have been reported ranging from rash to anaphylaxis.
Gastrointestinal disorders:
Not known: nausea, vomiting, abdominal pain or discomfort, blackening of stools, diarrhoea and/or constipation, mouth ulceration (in the context of incorrect administration, when the tablets are chewed, sucked or kept in mouth. Elderly patients and patients with deglutition disorders may also be at risk of oesophageal lesions or of bronchial necrosis, in case of false route).
Ascorbic acid is usually well tolerated. However, large doses are reported to cause diarrhoea and other gastrointestinal disturbances and are associated with the formation of renal calcium oxalate calculi. 4) Reporting of suspected adverse reactions Reporting suspected adverse reactions after authorisation of the medicinal product is important.
It allows continued monitoring of the benefit/risk balance of the medicinal product. uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store.

GBOfficial regulatory label· Warnings and precautions· revised October 4, 2024[1]

Ferrograd C tablets should be kept out of children's reach. Acute iron poisoning occurs rarely in adults, however it could happen if children swallow this medication.
The label will state ‘Important warning:
Contains iron. Keep out of the reach and sight of children, as overdose may be fatal’. This will appear on the front of the pack within a rectangle in which there is no other information. The prolonged release tablet and its inert plastic matrix may cause a safety hazard in some elderly or other patients suffering from delayed intestinal transit.
Iron preparations colour the faeces black, which may interfere with tests used for detection of occult blood in the stools. The guaiac test occasionally yields false positive tests for blood. Due to the risk of mouth ulcerations and tooth discolouration, tablets should not be sucked, chewed or kept in the mouth, but swallowed whole with water.
Aspiration of iron sulfate tablets can cause necrosis of the bronchial mucosa which may result in coughing, haemoptysis, bronchostenosis and/or pulmonary infection (even if aspiration happened days to months before these symptoms occurred).
Elderly patients and patients who have difficulties swallowing should only be treated with iron sulfate tablets after a careful evaluation of the individual patient’s risk of aspiration. Alternative formulations should be considered.
Patients should seek medical attention in case of suspected aspiration.

This is not medical advice. Consult a qualified healthcare professional.